Advertisement

Topics

Boehringer Ingelheim starts phase III interchangeability trial for adalimumab biosimilar

04:47 EDT 8 Sep 2017 | Generics and Biosimilars Initiative

Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) announced on 27 July 2017 that the first patient had been enrolled into the phase III VOLTAIRE‑X interchangeability study of its adalimumab biosimilar (BI 695501). The company says the trial ‘is the first study in the US to investigate an interchangeability designation for an adalimumab biosimilar candidate’.

Original Article: Boehringer Ingelheim starts phase III interchangeability trial for adalimumab biosimilar

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim starts phase III interchangeability trial for adalimumab biosimilar"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...